Results 61 to 70 of about 14,660 (227)

Chronic myeloid leukemia: past, present, future [PDF]

open access: yesEinstein (São Paulo), 2011
The discovery of the Philadelphia chromosome in 1960, and of theBCR-ABL oncogene in 1984, enabled the development in subsequentyears of a targeted therapy that revolutionized the treatment of chronic myeloid leukemia, thus changing its natural history ...
Patricia Weinschenker Bollmann   +1 more
doaj   +4 more sources

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice

open access: yesActa Médica Portuguesa, 2019
Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment.
Antonio Almeida   +10 more
doaj   +1 more source

Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells. [PDF]

open access: yesPLoS ONE, 2012
BACKGROUND: The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia.
Ludovic Belle   +6 more
doaj   +1 more source

Chronic myeloid leukemia-clinical, experimental and health economic studies with special reference to imatinib treatment [PDF]

open access: yes, 2013
CML is a malignant disease that originates in the bone marrow stem cell, carrying the Philadelphia chromosome with the BCR-ABL fusion gene. This gene translates into an active tyrosine kinase, Bcr-Abl, affecting hematopoiesis, particularly resulting in ...
Ohm, Lotta
core   +1 more source

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia [PDF]

open access: yesFarmacia Hospitalaria, 2015
Objectives: To describe the implementation of a new model face to face and remote pharmaceutical care with home delivery of tyronsine kinase inhibitors medicines for patients with chronic myeloid leukemia.
Begoña San José Ruiz   +2 more
doaj   +1 more source

Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML [PDF]

open access: yes, 1991
Between 1985 and 1989, many cases of Philadelphia (Ph) chromosome negative chronic myelogenous leukemia (CML) were reported. For this review, the following selection criteria were used: the original articles on Ph-negative cases should provide clinical ...
Grosveld, G.C. (Gerard)   +2 more
core   +1 more source

Novel clinical trial designs emerging from the molecular reclassification of cancer

open access: yesCA: A Cancer Journal for Clinicians, Volume 75, Issue 3, Page 243-267, May/June 2025.
Abstract Next‐generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease,
Mina Nikanjam   +4 more
wiley   +1 more source

Combination therapy using TGF-β1 and STI-571 can induce apoptosis in BCR-ABL oncogene-expressing cells

open access: yesBiomolecular Concepts, 2021
The BCR-ABL oncogene is a tyrosine kinase gene that is over-expressed in CML. It inhibits the TGF-β1 signaling pathway. Due to resistance of cells to the tyrosine kinase inhibitor, STI-571, the combined effect of STI-571 and TGF-β1 on K562 cells was ...
Bakhshayesh Masoome   +3 more
doaj   +1 more source

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]

open access: yes, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem   +19 more
core   +1 more source

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

open access: yes, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V.   +23 more
core   +1 more source

Home - About - Disclaimer - Privacy